Sheet I of 2 Application Number 09/765,060 Docket Number 494492000100 Form PTO-1449 Applicant INFORMATION DISCLOSURE CITATION Baofa YU IN AN APPLICATION Group Art Unit 1642
RECEIVED Use several sheets if necessary) Filing Date January 17, 2001 Mailing Date November 24 . 2002 DEC 0 4 2002 TECH CENTER 1600/2900 U.S. PATENT DOCUMENTS Subclass Filing Date If Examiner Ref. Date Document No. Name Class **Appropriate Initials** No. KAC 1. 05/1984 435 7 4,447,526 Rupchock et al. 2. 02/1988 4,724,230 514 558 Cone, Jr 3. 04/1991 5,005,588 Rubin 128 804 4. 424 277.1 10/1992 5,156,841 Rapp 5. 06/1993 5,215, 899 Dattagupta 435 6 03/1994 5,290,551 424 88 6. Berd 7. 07/1997 5,651,986 Brem et al. 424 484 8. 01/1998 5,705,151 Dow et al. 424 93.21 9 12/1998 5,846,565 Brem et al. 424 486 FOREIGN PATENT DOCUMENTS Examiner Ref. Subclass Translation Date Document No. Country Class **Initials** YES NO No. rAL 10. 02/2000 WO 00 06143 **WIPO** 11. 04/1997 WO 97/11666 **WIPO** 12. 01/1998 WO 98/03195 WIPO 13. 09/1999 WO 99/46385 **WIPO** EP 14. 07/1990 0 378 888 15. 11/1982 2 505 182 FR OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.) Title Examiner Ref. Initials No. KA C 16. Adams. Poult. Sci. 49(1):229-33 (1970) 17. Auerbach. Pharmacol. Ther. 63(3):265-311 (1994) 18. August. Clin. Dermatol. 13(6):589-92 (1995) 19. Aw. "Molecular and Cellular Responses to Oxidative Stress and Changes in Oxidation-Reduction EXAMINER: (examiner) DATE CONSIDERED: ancele arm EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO 1449			Docket Number 494492000100	Application Number 09/765,060	
PIFORMATION DISCLOSURE CITATION			Applicant		
AN AN APPLICATION			Baofa YU		
DEC 0 3	The co	se several sheets if necessary)	Filing Date January 17, 2001	Group Art Unit 1642	
PRADE			Mailing Date November 21 . 2002		
TRADE	MARKE				
		Imbalance in the Intestine" (Abstract)	at <http: www.ajcn.org=""> (visite</http:>	d on June 6, 2002)	
KAL 20. / Awwad et al. Cancer Immunol		Awwad et al. Cancer Immunol. Immur			
	21. Berd, et al. Cancer Research 46:2572		2577 (1986) RECEIVED		
	22.	Berd et al. Cancer Research 51:2731-2	734 (1991)	DEC 0 4 2002	
	23.	Berd et al. Journal of Clinical Oncolog	y 15(6):2359-2370 (1997)	DEC 0 4 2002 .	
1.	24.	Berd et al. Seminars in Oncology 25(6)):646-653 (1998)	TECH CENTER 1600/2000	
	25.	Berd. Seminars in Oncology 25(6):605-610 (1998)			
	26.	Bier et al. "Intratumor Immunotherapy with BCG Cell Wall Preparations: Development of a New Therapy Approach for Head-Neck Tumors" (abstract) at http://www.ncbi.nim.nih.gov (visited on November 24, 1999)			
	27.	Bingya et al. Chin. J. Oncol. 20(1):34-3	36 (1998)		
	28. Biochemistry 11(9):1726 (1972)				
	29.	Bromberg et al. The Cancer Journal fro	om Scientific American pp.132-3	38 (1999)	
	30.	Brunschwig et al. J. Immunother. 22(5):390-400 (1999)			
	31.	Chakraborty et al. Cancer Immunol. In	nmunother. 47:58-64 (1998)		
	32.	Calsini et al. "Immunotherapy of Bladder Cancer with Intralesional Injection with BCG" (Abstract) at http://www.ncbi.nlm.nih.gov (visited on November 24, 1999)			
	33.	Chamberlain. Drugs 57)3):309-325 (1999)			
	34.	Chang et al. Int. J. Radiat. Oncol. Biol.	Phys. 40(1):65-70 (1998)		
	35.	Chang et al. Br. J. Plast. Surg. 52(3):17	78-81 (1999)		
	36.	Chassoux et al. "Therapeutic Effect of Intratumoral Injection of bcg and Other Substances in Rats and Mice" (Abstract) at http://www.ncbi.nim.nih.gov (visited on November 24, 1999)			
	37.	Chen et al. Journal of Biomedical Scient	nce 5:231-252 (1998)		
	38. Chen et al. The Cancer Journal from Scientific American pp.16-17 (1999)			99)	
	39. Claman. Journal of Immunology 116(3):704-9 (1976)				
	40. /	Dieli et al. Int. Immunol. 9(1):1-8 (1997)			
	41.	Duda et al. Annals of Surgical Oncology 2(6):542-9 (Abstract) (1995)			
	42.	Fisher at al. "Comparative Effects of Corynebacterium Parvum, Brucella Abortus Extract, Bacillus Calmette-Guerin, Glucan, Levamisole, and Tilorone With or Without Cyclophosphamide on Tumor Growth, Macrophage Production, and Macrophage Cytotoxicity in a Murine Mammary Tumor Model" (Abstract) at http://www.ncbi.nlm.nih.gov (visited on November 24, 1999)			
	43.	Fujiwara et al. Journal of Immunology 132(3):1571-1577 (1984)			
V	44.	Gavrilenko et al. Vopr. Onkol. 29(4):6	7-70 (1983)		
EXAMINER: Karin a. Gamille DATE CONSIDERED: 9/20/03					
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					

For	m-PTC	<u>)</u> -1449		Docket Number 494492000100	Application Number 09/765,060	
O INFORMATION DISCLOSURE CITATION		ON DISCLOSURE CITATION	Applicant			
NET. 0 3 2002 IN AN APPLICATION			AN APPLICATION	Baofa YU		
DEC	, U J De-		se several sheets if necessary)	Filing Date January 17, 2001	Group Art Unit 1642	
ENT.	THAUEMAS			Mailing Date November 21 . 2002	RECEIVED	
		45.	Gilboa. Cancer Immunol. Immunother	- 48·282-285 (1000)	DEC A 4 ages	
K	AC	46.	Goldberg et al. Radiology 209(2):371-	520 6 4 7007		
	+-	47.	Goldberg et al. Radiology 209(2):761-		TECH CENTER 1600/2900	
	+	48.	Goldberg et al. Radiology 213(2):438-44 (1998)			
		49.	Haas et al. "An Effective Strategy Human Tumor Vaccine Modification by Coupling Bispecific Costimulatory Molecules" (Abstract) at http://www.cdlib.org (visited on November 28, 1999)			
	1.	50. Haba et al. Int. J. Cancer 18(1):93-104 (1976)				
		51.	Hageboutros et al. Investigational Nev			
		52.	Hawkins. Current Opinion in Oncolog	<u>``</u>		
		53.	Helting et al. Acta Pathol. Microbiol.	<u> </u>	984)	
		54.	Henderson. "Regression of Lung Metastases After Immunotherapy with Autologous, DNP-Modified Melanoma Vaccine" (Abstract) at http://www.cdlib.org (visited on September 7, 1999)			
		55.	Henderson et al. "Advances in Conventional Treatment of Breast Cancer: The Addition of BCG and Autotumour Vaccine Immunotherapy" (Abstract) at http://www.cdlib.org (visited on September 7, 1999)			
		56.	Henderson. "Cancer Immunotherapy Autologous Melanoma Cell Vaccine Generates Immunity" (Abstract) at http://www.cdlib.org (visited on September 7, 1999)			
		57.	Hess Eur. J. Immunol. 6(3):188-93 (19	976)		
		58.	Holmes et al. "Intralesional BCG Imm http://ncbi.nim.nih.gov (visited on I		ors" (Abstract) at	
		59.	Im et al. J. Biol. Chem. 260(8):4591-7	(1985)		
		60.	Inouye et al. J. Clin. Microbiol. 20(3):	525-9 (1984)		
		61.	Jiao et al. Br. J. Surg. 86(9):1224 (199	9)		
		62.	Jinglin et al. Chin. J. Oncol. 19(5):333	-335 (1997)		
		63.	Ziegler, J. J. Natl. Cancer Instit. 88:78	6-788 (1996)		
		64. Jocham. Recent Results Cancer Res. 126:135-42 (1993)				
		65.	Kasuga et al. "Experimental Study on Local Immunochemotherapy" (Abstract) at http://www.ncbi.nlm.nih.gov (visited on November 24, 1999)			
		66.	Kasuga et al. "Intratumor Chemoimmunotherapy with Mitomycin C and BCG in C3H/He Mice Transplanted with MH134" (Abstract) at http://www.ncbi.nlm.nih.gov (visited on November 24, 1999)			
		67.	Katz et al. J. Immunol. 107(5):1319-28	8 (1971)		
V	/	68.	Kelkar et al. "Antitumor Activity of Lactic Acid Bacteria on a Solid Fibrosarcoma, Sarcoma-180 and Ehrlich Ascites Carcinoma" (Abstract) at http://www.ncbi.nlm.nih.gov (visited on November 24,			
EXAMINER: Mun J. Ganella DATE CONSIDERED: 9/20/03						
E c	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					

PTO/SB/ 08 (2-92) sd-51952

Form PTO-1449			Docket Number 494492000100	Application Number 09/765,060
O TOP ORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Baofa YU	
0 0 2002	χC58 (υ	se several sheets if necessary)	Filing Date January 17, 2001	Group Art Unit 1642
DEC 0 3 2002 (E)			Mailing Date November 21 . 2002	<u> </u>
<u>ک</u> و مرخ				RECFIVED
TRADEMARK	1	1999)		
KAC	69.	Klekamp et al. Arch. Biochem. Bioph	ys. 246(2):783-800 (1986)	DEC 0 4 2002
	70.	Krup et al. Journal of Immunotherapy	22(6):525-38 (1999)	TEOU OF LITTE
	71.	Leong et al. Journal of Immunotherap	y 22(2):166-74 (1999)	TECH CENTER 1600/2900
	72.	Leung et al. Immunopharmacology 35	(3):255-63 (1997)	
	73.	Lillehoj et al. Avian Dis. 37(3):731-40	(1993)	
	74. /	Marzulli et al. Boll. Soc. Ital. Biol. Sp	er. 61(1):121-7 (1985)	
	75.	McHugh et al. Cancer Research 59:24	33-7 (1999)	
	76.	Menoret et al. Seminars in Oncology 2	25(6):654-660 (1998)	
	77.	Meulemans et al. Vet. Rec. 143(11):30	00-3 (1998)	
	78.	Miller et al. Journal of Immunology 1	17(5-1):1519-1526 (1976)	
	79.	Mizuno et al. Biochem. Mol. Biol. Int	. 47(4):707-14 (1999)	
	80.	Mizuochi et al. J. Immunol. 134(2):67	3-6 (1985)	
	81.	Nawrocki et al. Cancer Treatment Rev	views 25:29-46 (1999)	
	82.	Nogrady. Medicinal Chemistry. A Bio pp.388-392 (1985)	chemical Approach, Oxford Uni	iversity Press, New York,
	83.	Ohmoto et al. Am. J. Roentgenol. 173	(5):1231-3 (1999)	
	84.	O'Reilly. Investigational New Drugs	15:5-13 (1997)	
	85.	Otter et al. Cancer Immunol. Immuno	ther. 48:419-420 (1999)	
	86.	Pan et al. Biochemistry 37(5):1357-64	(1998)	
	87.	Presta et al. Cancer Research 59:2417-	-2424 (1999)	
	88.	Robinson et al. "Prostate Carcinoma: Ahttp://www.ncbi.nim.nih.gov> (visite		" (Abstract) at
	89.	Saha et al. Int. J. Rad. Appl. Instrum.	16(4):431-3 (1989)	
	90.	Saitoh et al. Urology 43(3):342-8 (199	04)	
	91.	Sakagami et al. Biochem. Biophys. Re	es. Commun. 155(2):650-5 (1988	3)
	92. _r	Santini et al. Free Radic. Biol. Med. 2	0(7):915-24 (1996)	
	93.	Sato et al. Clinical Immunology and Ir	nmunopathology 85(3):265-272	(1997)
	94.	Scott et al. "Clinical Promise of Tumo September 9, 199)	ur Immunology" at <http: td="" www<=""><td>.cdlib.org> (visited on</td></http:>	.cdlib.org> (visited on
,	95.	Seifert et al. World J. Surg. 23(10):10	19-26 (1999)	
96. Seiler et al. Recent Results Cancer Res. 75:53-60 (1980)				
EXAMINER: Harin J. Gamilla DATE CONSIDERED: 9/20/03				9/20/03
		al if citation considered, whether or not the citation considered. Include a copy of this form with n		ine through the citation if not in

Form PTO-1449				Docket Number 494492000100	Application Number 09/765,060	
INFORMATION DISCLOSURE CITATION			ON DISCLOSURE CITATION	Applicant		
IN AN APPLICATION			AN APPLICATION	Baofa YU		
(Use several sheets if necessary)			se several sheets if necessary)	Filing Date January 17, 2001	Group Art Unit 1642	
DEC 0 3 2002 55				Mailing Date November 21. 2002		
12 H	1, 00	27		<u> </u>		
Key,	£ 70.00	Seki et al. Am. J. Gastroenterol. 94(2):322-7 (1999)				
K	1 C	98. Serrou et al. "Unanticipated Effect of BCG in Mice Treated by Radiotherapy" (Abstract) at http://www.ncbi.nlm.nih.gov (visited on November 25, 1999)				
		99.	Shchepetkin. "Hypoxic Bioreductive Agents: The Possible Immune and Receptor-Mediated Mechanisms of Antitumor Action" (Abstract) at http://www.ncbi.nlm.nih.gov (visited on November 25, 1999)			
		100.	Shields et al. Ophthalmology 105(4):581-90 (1998)			
		101.	Sinn et al. Anal. Biochem. 170(1):186-92 (1988)			
		102.	Sparks et al. "Effect of Isonicotinic Acid Hydrazide on the Intratumor Injection of BCG" (Abstract) at http://www.ncbi.nim.nih.gov (visited on November 24, 1999)			
		103.	Stjarnkvist et al. J. Pharm. Sci. 80(5):436-40 (1991)			
		104.	Strashinin et al. Vopr. Onkol. 17(1):78-9 (1971) DEC 0 4 2002		DEC 0 4 2002	
		105.	Tarin et al. Mol. Hum. Reprod. 2(12):895-901 (1996)			
		106.	Toda et al. Human Gene Therapy 10(3):385-93 (1999) TECH CENTER 1600/29			
		107.	Vahrmeijer et al. Cancer Chemother. Pharmacol. 44(2):111-6 (1999)			
		108.	Wakeling. "The Latest Weapon in the War Against Cancer (Adoptive Immunotherapy) (Cover Story)" at http://www.cdlib.org (visited on September 7, 1999)			
J.		109.	Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Beiacmin/Cummings Pub. co., p.224.			
		110.	Wozniak et al. Bioorg. Med. Chem. Lett. 8(19):2641-6 (1998)			
		111.	Yu et al. J Current Oncology 1:97-100 (1994)			
<u></u>	1,	112.	Zastrow. Padiatr. Grenzgeb. 24(3):229	9-36 (1985)		
113. / Zhang et al. Melanoma Research 8(6):510-5 (1998) (Abstract)						

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.